InsidersTradesSigma
Track the INSULET CORP share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, INSULET CORP has logged 206 reports. Market capitalisation: €10.3bn. The latest transaction was reported on 24 August 2026 (Acquisition). Among the most active insiders: Benjamin Eric. Every trade is free.
206
Insider Decl.
n/a
Thresholds
€4m
8 ops.
Buy Volume
€15m
29 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate INSULET CORP Buy (bullish), based on 22 analysts. Average price target: US$171.91.
41Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,099 of 29,056 companies
57.5
score / 100
Value41
Quality74
FCF yld3.4%
Earn yld2.4%
EV/EBITDA23.0x
ROE26%
Gross mgn72%
Net mgn9.1%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 August 2026
Declarations206 total
1,100 shares@ US$147.47Common StockSEC:0001145197-26-000172:0
Canonical exit: 19 Nov 2026 (T+90)
151 shares@ US$152.250.0002% mcap100.0% of flowCommon StockSEC:0001145197-26-000159:0
418 shares@ US$143.270.0005% mcap10.0% of flowCommon StockSEC:0001145197-26-000142:0
1,660 shares0Common StockSEC:0001145197-26-000122:0
1,660 shares0Common StockSEC:0001145197-26-000123:0
207 shares@ US$246.613.9% of flowCommon StockSEC:0001145197-26-000075:0
200 shares@ US$246.6112.6% of flowCommon StockSEC:0001145197-26-000074:0
119 shares@ US$246.613.5% of flowCommon StockSEC:0001145197-26-000073:0
644 shares@ US$246.614.2% of flowCommon StockSEC:0001145197-26-000071:0
411 shares@ US$246.619.8% of flowCommon StockSEC:0001145197-26-000072:0
2,140 shares0Common StockSEC:0001145197-26-000065:0
1,044 shares0Common StockSEC:0001145197-26-000064:0
611 shares0Common StockSEC:0001145197-26-000063:0
1,885 shares0Common StockSEC:0001145197-26-000062:0
3,822 shares0Common StockSEC:0001145197-26-000061:0
2,140 shares0Common StockSEC:0001145197-26-000060:0
3,822 shares0Common StockSEC:0001145197-26-000059:0
10,046 shares0Common StockSEC:0001145197-26-000058:0
2,030 shares@ US$246.2331.3% of flowCommon StockSEC:0001145197-26-000044:0
Canonical exit: 26 May 2026 (T+90)
4,300 shares@ US$239.35100.0% of flowCommon StockSEC:0001145197-26-000031:0
Canonical exit: 21 May 2026 (T+90)
2,532 shares0Common StockSEC:0001145197-26-000024:0
5,246 shares0Common StockSEC:0001145197-26-000023:0
1,808 shares0Common StockSEC:0001145197-26-000022:0
1,808 shares0Common StockSEC:0001145197-26-000021:0
7,236 shares0Common StockSEC:0001145197-26-000020:0
25 of 206 declarations
关于 INSULET CORP
Insulet Corp. (NASDAQ: PODD) 是一家总部位于美国马萨诸塞州阿克顿的美国医疗技术公司。对于讲法语的投资者来说，它最好被理解为一家专注于糖尿病的医疗技术企业，而非一家广泛的医疗保健综合企业。Insulet 成立于 2000 年，其业务围绕无管胰岛素输送和自动化胰岛素管理展开，主要以 Omnipod 品牌销售。该公司的投资案例集中于创新、持续的患者采用以及差异化的产品架构，这在糖尿病护理的专业领域中形成了有意义的进入壁垒。([investors.insulet.com](https://investors.insulet.com/news/news-details/2026/Insulet-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx?utm_source=openai)) Insulet 的核心业务是 Omnipod 系列产品，尤其是 Omnipod 5，这是一种旨在与兼容的连续血糖监测技术协同工作的自动化胰岛素输送系统。该产品旨在通过消除导管、限制每日注射并支持更无缝的血糖控制来减轻糖尿病管理的负担。实际上，这使得 Insulet 相对于传统胰岛素泵和多次每日注射方案具有强大的定位，特别是对于寻求便利性、隐蔽性和数字集成的患者和临床医生。该公司还销售相关的软件功能、控制器和患者支持服务，这些都有助于加强使用、依从性和品牌忠诚度。([investor.insulet.com](https://investor.insulet.com/news/news-details/2026/Insulet-Redefines-Diabetes-at-CES-with-Liveable-Technology--A-New-Frontier-in-Human-Centered-Connected-Health/default.aspx?utm_source=openai)) 从竞争角度来看，Insulet 在无管胰岛素泵技术领域占据领先地位。管理层将该公司描述为该领域的全球领导者，最近的披露表明 Omnipod 5 已在 19 个国家/地区上市，支持其在美国本土之外不断增长的国际足迹。产品差异化和地域扩张的结合对投资者来说很重要，因为它表明在成熟和新兴糖尿病市场中都有很长的渗透空间。([investors.insulet.com](https://investors.insulet.com/news/news-details/2026/Insulet-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx?utm_source=openai)) 近期新闻总体上是积极的。2026 年 2 月，Insulet 报告 2025 年收入同比增长 31%，反映出美国和国际市场的强劲商业势头。2025 年 12 月，该公司获得美国 FDA 510(k) 许可，用于 Omnipod 5 的算法增强，包括更低的血糖目标选项和旨在使自动化使用更无缝的改进。2026 年 3 月，Insulet 宣布对某些美国 Omnipod 5 Pod 批次进行自愿医疗器械纠正，同时声明预计不会对发货或新患者启动造成干扰。总而言之，这些发展突出了一家具有强劲增长、持续产品创新和医疗技术固有的正常执行风险的企业。([investors.insulet.com](https://investors.insulet.com/news/news-details/2026/Insulet-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx?utm_source=openai))
